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A 27 year old woman with a recent diagnosis of polycystic
ovary syndrome comes to see you. She wants to know more
about the condition and the consequences for her health (box
1).
What you should cover
Find out what the patient understands about her condition and
explore how it is affecting her. Consider covering:
• her periods
• family plans
• acne or hirsutism
• metabolism
• wellbeing.
Irregular periods Prolonged oligomenorrhoea or amenorrhoea
can increase the risk of endometrial hyperplasia and cancer.3
Women who have polycystic ovary syndrome are three times
more likely to develop cancer than women who do not, but a
systematic review showed that around nine out of 10 will not
develop the condition.4 5 The risk is probably reduced if women
bleed naturally or have an induced bleed every three months
(fig 2⇓). Don’t assume that oligomenorrhoea in affected women
is always their polycystic ovary syndrome. New symptoms
should prompt consideration of other causes, such as pregnancy.
Subfertility/infertility—the risk of infertility is higher in women
who have few or no periods (oligomenorrhoeic/amenorrhoeic),
but even women who have regular periods can have difficulty
conceiving. Conversely, some women with polycystic ovary
syndrome have no fertility problems.
Acne—is present in 60%-80% of women who have polycystic
ovary syndrome.
Metabolism—Increasing obesity is associated with reduced
fertility, increased insulin resistance,6 and increased risk of
complications in pregnancy, such as miscarriage and
pre-eclampsia.7
Wellbeing—offer the option to talk about symptoms and signs
of depression and anxiety. Rates of depression and anxiety are
more common in women who have polycystic ovary syndrome
compared with the general population.
What you should do
Polycystic ovary syndrome is associated with various health
consequences that might need to be monitored over time.
Irregular periods—assuming that the woman does not want to
conceive, clarify the frequency of her periods. If she is having
less than one period every three months, discuss inducing
withdrawal bleeds8 9 to reduce the risk of endometrial
hyperplasia (fig 2⇓). The choice of hormonal treatment should
be tailored to the individual. For example, those who also suffer
from acne/hirsutism or who want regular bleeds may want to
take the combined oral contraceptive pill. Those requiring long
term contraception or who have heavy irregular periods may
wish to consider an intrauterine system, and patients who would
rather not take regular hormonal contraceptives could take
cyclical progesterones. All patients should have an initial pelvic
ultrasound to assess endometrial thickness. If the patient chooses
not to take hormones, refer her to a specialist and carry out
ultrasound assessment for endometrial hyperplasia every 6-12
months.8Aswomenwith polycystic ovary syndrome have some
ovarian activity, there is no need to offer osteoporosis
prophylaxis.10
Subfertility/infertility—if the woman is having difficulty
conceiving, refer her to a fertility specialist for further
investigations after six months if she is oligomenorrhoeic or
amenorrhoeic, or is over the age of 36.11
Acne—there are few data on the efficacy of treatments for acne
in those with polycystic ovary syndrome.12 Offer a combined
oral contraceptive as a first line treatment, which can be used
to treat acne and hirsutism and induce withdrawal bleeds.
Beyond this, offer topical retoinoids, topical antibiotics, oral
antibiotics, or a combination of all three in line with general
guidance on acne.13
Metabolism—advise weight loss in those who are overweight.
Losing weight, improving diet, and increasing exercise also
reduce insulin resistance and increase the chances of
conception.14 The British Fertility Society suggests that a loss
of 5-10% in body weight can be enough to restore fertility and
improve metabolic markers.14
Insulin resistance is present in up to 80% of women who have
polycystic ovary syndrome. The use of metformin or other drugs
that increase sensitivity to insulin are not recommended in the
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What you need to know
• In women with less than one period every three months, manage the risk of endometrial hyperplasia and aim to induce a withdrawal
bleed
• Review women who are considering pregnancy and consider early referral to a fertility service
• Combined oral contraceptives are the first line of choice for women who have polycystic ovary syndrome and acne
Box 1: Background facts
Polycystic ovary syndrome affects 6%-7% of women.1
Women may experience
• oligomenorrhoea
• anovulatory fertility
• hyperandrogenism2 and the clinical symptoms and signs of hirsutism
• acne
The relation between polycystic ovary syndrome and obesity is poorly understood. Polycystic ovary syndrome is not caused by, and does
not cause, obesity. However, obesity is associated with an increase in secondary complications in women with polycystic ovary syndrome,
such as:
• impaired glucose tolerance
• type 2 diabetes
• sleep apnoea
• adverse cardiovascular profile (including hypertension, dyslipidaemia, and insulin resistance) (fig 1⇓)
absence of type 2 diabetes.15Offer women annual measurements
of fasting glucose.16
Share information with the patient on factors associated with
polycystic ovary syndrome (box 1).
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Diagnostic criteria for polycystic ovary syndrome
Require two out of three of the following criteria:
• Infrequent or no ovulation (usually recognised as infrequent or no menstruation)
• Clinical or biochemical evidence of hyperandrogenism
o Clinical=hirsutism, acne, male pattern alopecia
o Biochemical=high levels of total or free testosterone
• Polycystic ovaries on ultrasonography=12 or more follicles in at least one ovary, measuring 2-9 mm diameter, or increased ovarian
volume (>10 mL) (fig 3⇓)
These criteria are based on guidelines from the Rotterdam ESHRE/ASRM sponsored PCOS Consensus workshop group. Revised 2003
consensus on diagnostic criteria and long term health risks related to polycystic ovarian syndrome. Fertil Steril 2004;81:19-25.
Further reading
National Institute for Health and Care Excellence. Polycystic ovary syndrome. 2013. http://cks.nice.org.uk/polycystic-ovary-syndrome
Royal College of Obstetrician and Gynaecologists Greentop Guidelines. Long-term Consequences of Polycystic Ovary Syndrome. 2014.
www.rcog.org.uk/globalassets/documents/guidelines/gtg_33.pdf
Education into practice
• Think about the last time that you saw a woman with polycystic ovary syndrome. Is there anything that you can take from this article
to support her care better?
• Do you offer women with polycystic ovary syndrome annual measurements for fasting glucose?
• Do you routinely address psychological issues in women who have polycystic ovary syndrome?
How patients were involved
I consulted a patient with a diagnosis of polycystic ovary syndrome, asking specific questions around how the diagnosis was delivered and
what information she was given.
She emphasised the importance of sensitive communication in discussing the impact of polycystic ovary syndrome on her life. She would
have welcomed clearer discussion of the effects on fertility and contraception, as well as longer term issues such as the risk of type 2
diabetes. She thought that the psychological impact of the diagnosis could have been underestimated by her doctors. I used her experiences
to help GPs swiftly discuss many issues regarding polycystic ovary syndrome in one consultation
Figures
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Fig 1 A diagram showing the interaction between the hormonal profile and metabolic features of polycystic ovary syndrome
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Fig 2 Protocol for managing withdrawal bleed and assessment of endometrial thickness 8
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Fig 3 3D ultrasound of a polycystic ovary
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